Olink Holding AB ADR (OLK) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Olink Holding AB ADR stock (OLK) is currently trading at $26.08. Olink Holding AB ADR PS ratio (Price-to-Sales) is 18.98. Analyst consensus price target for OLK is $26.00. WallStSmart rates OLK as Sell.
- OLK PE ratio analysis and historical PE chart
- OLK PS ratio (Price-to-Sales) history and trend
- OLK intrinsic value — DCF, Graham Number, EPV models
- OLK stock price prediction 2025 2026 2027 2028 2029 2030
- OLK fair value vs current price
- OLK insider transactions and insider buying
- Is OLK undervalued or overvalued?
- Olink Holding AB ADR financial analysis — revenue, earnings, cash flow
- OLK Piotroski F-Score and Altman Z-Score
- OLK analyst price target and Smart Rating
Olink Holding AB ADR
📊 No data available
Try selecting a different time range
Smart Analysis
Olink Holding AB ADR (OLK) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Olink Holding AB ADR (OLK) Key Strengths (1)
Mid-cap company balancing growth potential with stability
Olink Holding AB ADR (OLK) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 19.0x annual revenue
Very expensive at 7.0x book value
Revenue growing slowly at 4.70% annually
Moderate institutional interest at 35.23%
Supporting Valuation Data
Olink Holding AB ADR (OLK) Detailed Analysis Report
Overall Assessment
This company scores 17/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 7.0/10) while 7 fall into concern territory (avg 1.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Market Cap.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (18.98), Price/Book (7.02) suggest expensive pricing. Growth concerns include Revenue Growth at 4.70%, which may limit upside. Profitability pressure is visible in Return on Equity at -7.03%, Operating Margin at -86.80%, Profit Margin at -19.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -7.03% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 4.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
OLK Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
OLK's Price-to-Sales ratio of 18.98x trades 33% below its historical average of 28.14x (37th percentile). The current valuation is 78% below its historical high of 85.94x set in Jul 2021, and 45% above its historical low of 13.11x in Sep 2023.
WallStSmart Analysis Synopsis
Data-driven financial summary for Olink Holding AB ADR (OLK) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Olink Holding AB ADR is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 171M with 470% growth year-over-year. The company is currently unprofitable, posting a -19.7% profit margin.
Key Findings
Revenue growing at 470% YoY, reaching 171M. This pace significantly outperforms most DIAGNOSTICS & RESEARCH peers.
The company is unprofitable with a -19.7% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -8M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Olink Holding AB ADR maintain 470%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Olink Holding AB ADR.
Bottom Line
Olink Holding AB ADR is a high-conviction growth story with revenue accelerating at 470% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -19.7% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Olink Holding AB ADR(OLK)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Olink Holding AB (publ) provides various products and services for academic, government, biopharmaceutical, biotechnology and other institutions focused on life science research. The company is headquartered in Uppsala, Sweden.